Veliparib 2HCl
PARP 1&2 inhibitor / Potent and selective PARP-inhibitor with Ki values of 5.2 nM and 2.9 nM for PARP-1 and PARP-2, respectively.1 Restores sensitivity to DNA alkylator/methylator temozolomide in glioma cells and xenografts2, and enhances radiotherapy sensitivity in endometrial carcinoma cells3. Also improves sensitivity to DNA replication inhibitor cisplatin in human oral carcinoma cells.4
Biochemicals & reagents
912445-05-7
ABT-888
1 Donawho et al. (2007), ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models; Clin. Cancer Res., 13 2728 2 Yuan et al. (2018), ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts; PLoS One, 13 e0202860 3 Wang et al. (2022), Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma; J. Clin. Lab Anal., 36 e24435 4 Paterniti et al. (2021), Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, improved Cisplatin Effect in Human Oral Cell Carcinoma; Biomedicines, 9 771
-20°C
TARGET: PARP -- PATHWAY: DNA repair; DNA damage -- DISEASE AREA: Cancer